ÀÚ·á½Ç
  • GMP °¡À̵å¶óÀÎ
  • ÇÁ·Î±×·¥ ´Ù¿î·Îµå
  • ±â¾÷ȸ¿ø ÀÚ·á½Ç
GMP °¡À̵å¶óÀÎ
±¸ºÐ¼±
GMP °¡À̵å¶óÀÎ °Ô½ÃÆÇ
Á¦¸ñ [EMA] What are the GMP Responsibilities of the Marketing Authorisation Holders?
µî·ÏÀÏ 2016-11-01 Á¶È¸¼ö 1,061
÷ºÎÆÄÀÏ WC500213610_20161101.pdf  
³»¿ë

¾È³çÇϼ¼¿ä.

EMA(European Medicines Agency)ÀÇ GMP/GDP IWG(Inspectors Working Group)¿¡¼­ ÀǾàǰ ÆÇ¸Å Çã°¡ º¸À¯ÀÚ(Marketing Authorisation Holders, MAH)ÀÇ GMP Ã¥ÀÓÀ» ¿ä¾àÇÑ Concept Paper¸¦ ¹ßÇàÇÏ¿´½À´Ï´Ù.

´ÙÀ½Àº °£´ÜÈ÷ ¿ä¾àÇÑ ³»¿ëÀÔ´Ï´Ù.

  • Chapter 1: responsibility to evaluate the results of the PQR review
  • Chapter 7: responsibility to put contracts in place
  • Chapter 8: responsibilities concerning quality defects, risk-reducing actions and notification of possible disruption in supply
  • Annex 2: responsibility to put contracts in place
  • Annex 12: obligations to approve the design of irradiation cycles, and agreeing the location for retention of irradiation cycle records.
  • Annex 16: requirement to identify the site and QP responsible for certifying each batch (in the case of multiple sites authorised to manufacture / import / certify the same product) and the statement that the "ultimate responsibility for the performance of a medicinal product over its lifetime, its safety, quality and efficacy" lies with the MAH
  • Annex 19: responsibilities for ensuring that reference and retention samples are taken, and stored.
GMP °¡À̵å¶óÀÎ °Ô½ÃÆÇ ÀÌÀü±Û
ÀÌÀü±Û [EMA] Annual Report of the GMP/GDP Inspectors Working Group published
GMP °¡À̵å¶óÀÎ °Ô½ÃÆÇ ´ÙÀ½±Û
´ÙÀ½±Û [MFDS] ¹ÙÀÌ¿ÀÀǾàǰ Á¦Á¶°øÁ¤ ¹ë¸®µ¥ÀÌ¼Ç °¡À̵å¶óÀÎ(Á¦3°³Á¤)
¸®½ºÆ®